An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

Gilead Sciences (NASDAQ ... Overview of Peer Analysis The peer analysis summary presents essential metrics for Vertex Pharmaceuticals, Regeneron Pharmaceuticals and Amgen, unveiling their ...

A Pennsylvania federal district court denied summary judgment to Gilead Sciences, Inc. on the wrongful discharge claim under state law of an employed at-will therapeutic specialist who sold its ...

Modera Wealth Management LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 8.9% in ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) is scheduled to release its earnings data after the market closes on Wednesday, November 6th. Analysts expect Gilead Sciences to post earnings of $1.66 ...

Scottish Medicines Consortium Accepts Kite CAR T-Cell Therapy for Earlier Use to Treat Aggressive Blood Cancers - First SMC acceptance of any CAR T-cell therapy for lymphoma patients in the ...

Gilead Sciences, Inc. (NASDAQ ... and median overall survival was not yet reached. In summary, we are encouraged by the compelling results so far, and with over 140 patients dosed across both the ...

Arcus Biosciences (RCUS) announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an ...

An in-depth analysis of recent analyst actions unveils how financial experts perceive Gilead Sciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ...